May 1, 2025 — Camgenium, a leading medical software engineering company, has announced further details of its partnership with Cardiac Tech to develop and deploy their new medical device product, Pace-Protect. This medical device has the potential to significantly improve patient outcomes following open-heart surgery by minimizing adverse events (AEs) related to temporary pacemakers.

At the SCAI 2025 Scientific Sessions in Washington, DC, SCAI President James B. Hermiller, MD, MSCAI, recognized several individuals for their outstanding service, leadership, and contributions to patient care.  

May 1, 2025 — A new expert opinion document jointly released by the Society for Cardiovascular Angiography and Interventions (SCAI) and the Society of Cardiovascular Computed Tomography (SCCT) presents a comprehensive framework for using coronary computed tomography angiography (CCTA) to guide percutaneous coronary intervention (PCI).

May 1, 2025 – Analyses from the (Ergonomics in the Cardiac Catheterization Laboratory (ERGO-CATH) study show the traditional approach using a lead apron causes 43% of interventional cardiologists to experience discomfort, building on existing consensus of the significant occupational health risks that exist in the catheterization (cath) lab. The data were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2025 Scientific Sessions in Washington, D.C.

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, has  announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation (BDD) for atrioventricular interval modulation (AVIM) therapy.

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for patients undergoing ascending aorta and aortic root surgery, with or without concomitant aortic valve replacement (AVR). This first-of-its-kind tool represents a major step forward in risk stratification and personalized surgical planning for complex aortic operations.

April 25, 2025 – Medtronic plc, a global leader in healthcare technology, recently received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement.

April 24, 2025 — HeartBeam, Inc. recently announced a strategic collaboration with AccurKardia to enhance the accessibility of cardiac monitoring solutions and will focus on making AccurKardia’s FDA-cleared ECG analysis software, AccurECG, available on HeartBeam’s devices.* 

April 27, 2025 – The Heart Rhythm Society (HRS) has announced the findings of new studies demonstrating the safety and efficacy of emerging pulsed field ablation (PFA) systems during Heart Rhythm 2025 in San Diego, California.  

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now